MedTrace Logo

A Pharmacogenomic Study of Candesartan in Heart Failure

NCT00400582 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2011-07-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of genetic variations on the response to candesartan in patients with heart failure who are already treated with an ACE inhibitor.

Conditions

Interventions

DRUG

Candesartan up to 32 mg daily

Candesartan 4 to 32 mg daily

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Montreal Heart Institute

    lead OTHER

Principal Investigators

  • Michel White, MD · Montreal Heart Institute

  • Simon de Denus, B. Pharm, MSc,PhD · Montreal Heart Institute/ Faculty of Pharmacy, University of Montreal

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400582 on ClinicalTrials.gov